Experiences with Irbesartan

This page shows detailed information about a medicine such as statistics, patient reviews and related articles.

Active ingredient: irbesartan
ATC Code: C09CA04

Level of
Satisfaction

Level of Satisfaction 25%

What patients say...

Effectiveness 100%
Quantity of side effects 37%
Severity of side effects 75%
Ease of use 87%

Our patients

Our patients, demographics

Read our patient's reviews about Irbesartan

Filter reviews by...

hide filters...
translation feature available for reviews from other countries
Irbesartan
31/07/2017 | | 63moderated by Henry
irbesartan (150mg) for high blood pressure

I had Lisinopril first of all, but it gave me a nasty cough. Then irbesartan. It was fine in the beginning but after about 10 months or so I noticed a loud ringing in my left ear. I spontaneously stopped taking this and the ringing has got less.
> read full review...

Irbesartan
22/07/2017 | | 49moderated by Susan
irbesartan (75mg) for high blood pressure

Blood pressure has sunk to 130/79 on 75 mg. In the beginning my head and body were so itchy it was not pleasant. But that has passed. However, I have got a lot of problems with a nasty cough that just won't go away. I had an ACE inhibitor before and had a cough with that too. Really irritating.
> read full review...

Most reviewed medicines


The content on this page is user-generated content, read and revised before approval to comply with our standards for a medicine review or reaction. We do not enforce any proven medical knowledge from our users to allow them to present their experiences. This way, the opinions and experiences described state only the views of the writers and not those of the owner of this website. Remember that these experiences differ from person to person and that you should always contact your doctor or pharmacist for advice on medication.

Copyright © 2008-2024 Insight Pharma Services BV.
All rights reserved.
Most icons from FontAwesome. Some icons made by Prosymbols from www.flaticon.com and licensed as CC 3.0 BY.